ENTERO THERAPEUTICS INC (ENTO) Stock Price, Quote, News and Overview
NASDAQ:ENTO - Nasdaq - US33749P4081 - Common Stock - Currency: USD
ENTO Quote, Performance and Key Statistics
ENTERO THERAPEUTICS INC
NASDAQ:ENTO (2/5/2025, 2:31:29 PM)
0.55
+0.01 (+1.81%)
The current stock price of ENTO is 0.55 USD. In the past month the price decreased by -12.87%.
ENTO Latest News, Press Releases and Analysis
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SUM, STAF, ALVR, ENTO on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBRDA, SUM, MNTX, ENTO on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAF, ATSG, ENTO, AVTE on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
ENTO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.99 | 339.64B | ||
| AMGN | AMGEN INC | 15.5 | 165.18B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 960.51 | 126.15B | ||
| GILD | GILEAD SCIENCES INC | 22.67 | 125.18B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.67 | 78.59B | ||
| ARGX | ARGENX SE - ADR | N/A | 40.21B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.51B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.38B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.37B | ||
| NTRA | NATERA INC | N/A | 23.31B | ||
| BIIB | BIOGEN INC | 8.93 | 21.24B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.66 | 15.92B |
Related stock screener links
About ENTO
Company Profile
First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 9 full-time employees. The company went IPO on 2016-10-11. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for multiple GI conditions, including gastroparesis, and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. The firm also intends to develop Niclosamide, an oral small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.
Company Info
ENTERO THERAPEUTICS INC
777 Yamato Road, Suite 502
Boca Raton FLORIDA US
Employees: 9
Company Website: https://enterothera.com/
Investor Relations: https://www.firstwavebio.com/investors/
Phone: 15615897020
ENTO FAQ
What is the stock price of ENTO?
The current stock price of ENTO is 0.55 USD.
What is the symbol for ENTERO THERAPEUTICS INC stock?
The exchange symbol of ENTERO THERAPEUTICS INC is ENTO and it is listed on the Nasdaq exchange.
On which exchange is ENTO stock listed?
ENTO stock is listed on the Nasdaq exchange.
Is ENTO a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ENTO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ENTO.
Does ENTO stock pay dividends?
ENTO does not pay a dividend.
What is the Short Interest ratio of ENTO stock?
The outstanding short interest for ENTO is 2.04% of its float.
ENTO Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ENTO.
ENTO Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ENTO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ENTO. The Buy consensus is the average rating of analysts ratings from 6 analysts.